Kochi, June 10 -- Servier India, a subsidiary of the leading French pharmaceutical Servier Group, has announced the launch of Ivosidenib (Tibsovo(R)), an oral targeted therapy approved in the management of cancer patients with Acute Myeloid Leukemia (AML) and Cholangiocarcinoma, with an isocitrate dehydrogenase-1 (IDH1) mutation.
Servier India received the approval on 14th May 2025, from Central Drugs Standard Control Organisation (CDSCO) for the import, sale, and distribution of the medication.
Acute myeloid leukemia is a challenging hematological malignancy. Studies indicate that only about 30-40 percent of AML patients in India receive adequate treatment, with high mortality rates due to rapid disease progression and infections.
Chola...